Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PHILLIP J GOLDSTEIN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1346406147
CMS profile
715307
Location
GREENVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,303.81

170 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,303.81 170

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PHILLIP J GOLDSTEIN

NPI 1346406147 · CMS profile ID 715307

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

GREENVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346406147?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346406147?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346406147?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1346406147?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

170 matching records · $3,303.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 170 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 170.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Braintree Laboratories, Inc. $20.3009/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1173777456 CMS
ABBVIE INC. $17.6909/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940274 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.5009/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223808566 CMS
Aimmune Therapeutics, Inc. $20.0109/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249697194 CMS
ABBVIE INC. $18.3409/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940270 CMS
ABBVIE INC. $1.5109/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940272 CMS
Ardelyx, Inc. $24.4609/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247850316 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.5709/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231982046 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.1808/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223795376 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.0808/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223819694 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.7208/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223811500 CMS
GENZYME CORPORATION $29.1608/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233380168 CMS
ABBVIE INC. $23.0808/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940268 CMS
ABBVIE INC. $27.8008/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940266 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.0308/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231982075 CMS
Janssen Biotech, Inc. $23.1308/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175091220 CMS
QOL Medical, LLC $17.6908/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184988508 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.3708/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223852020 CMS
PFIZER INC. $15.2908/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229186425 CMS
Lilly USA, LLC $17.6108/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186799773 CMS
Ardelyx, Inc. $21.9208/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247850314 CMS
Madrigal Pharmaceuticals $33.7207/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248264328 CMS
Aimmune Therapeutics, Inc. $28.5707/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249697206 CMS
ABBVIE INC. $15.2907/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940264 CMS
ABBVIE INC. $22.8407/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940262 CMS
Janssen Biotech, Inc. $14.4607/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175091541 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.0307/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231982072 CMS
PFIZER INC. $15.8907/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229005066 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.3707/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223909799 CMS
Ardelyx, Inc. $27.3907/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247850310 CMS
Ardelyx, Inc. $1.3607/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247850312 CMS
QOL Medical, LLC $19.7307/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184988494 CMS
Rhythm Pharmaceuticals, Inc. $22.4207/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240097580 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.2607/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223876300 CMS
Lilly USA, LLC $20.9107/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186799771 CMS
Celltrion USA Inc. $25.5707/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250823064 CMS
Janssen Biotech, Inc. $20.6806/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175090748 CMS
GENZYME CORPORATION $19.8606/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233380148 CMS
Intra-Sana Laboratories $16.6206/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251421368 CMS
Phathom Pharmaceuticals, Inc. $15.8806/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219329062 CMS
Ardelyx, Inc. $20.7206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247850308 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.8306/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231982065 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.0306/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231982068 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.7106/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223854837 CMS
ABBVIE INC. $23.6706/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940260 CMS
QOL Medical, LLC $16.4506/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184988480 CMS
ABBVIE INC. $15.7106/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940258 CMS
Regeneron Healthcare Solutions, Inc. $24.1106/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212929847 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.5306/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223816318 CMS
ABBVIE INC. $14.4906/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201940256 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,086.76 146
PY2020 $3,156.46 91
PY2021 $2,556.22 147
PY2022 $2,975.59 181
PY2023 $2,435.84 150
PY2024 $2,951.30 159
PY2025 $3,303.81 170

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $168,298.94 72
PY2024 Principal investigator $202,773.78 41
PY2023 Principal investigator $223,446.84 48
PY2022 Principal investigator $60,191.58 23
PY2021 Recipient $4,599.00 1
PY2021 Principal investigator $137,081.86 30
PY2020 Recipient $693.52 4
PY2020 Principal investigator $247,920.22 46
PY2019 Recipient $2,453.31 2
PY2019 Principal investigator $339,148.14 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,738.00 12/11/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244051831
Principal investigator 1 ABBVIE INC. $2,824.90 12/04/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202527334
Principal investigator 1 Eli Lilly and Company $4,750.00 12/03/2025 Non-covered Recipient Entity
RESEARCH ALLIANCE INC
MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS No dispute reported 06/30/2026 1187890380
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780102
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780104
Principal investigator 1 Boehringer Ingelheim International GmbH $1.00 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780106
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780150
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780152
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780154
Principal investigator 1 ABBVIE INC. $3,375.00 11/12/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202523817
Principal investigator 1 ABBVIE INC. $3,402.10 11/04/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202520197
Principal investigator 1 ABBVIE INC. $3,073.20 10/09/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202514235
Principal investigator 1 ABBVIE INC. $8,700.90 10/01/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202512922
Principal investigator 1 ABBVIE INC. $3,286.40 09/03/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202507303
Principal investigator 1 ABBVIE INC. $1,978.99 08/26/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202505899
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780094
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780096
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780098
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780100
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780142
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780144
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780146
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780148
Principal investigator 1 Genentech, Inc. $2,471.00 08/26/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211583960
Principal investigator 1 ABBVIE INC. $2,772.90 08/05/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202501422
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780090
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780092
Principal investigator 1 ABBVIE INC. $530.40 07/10/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202497912
Principal investigator 1 ABBVIE INC. $1,589.90 07/02/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202495245
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,403.00 07/02/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282046
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,871.90 07/02/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282054
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,362.00 07/02/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282132
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,668.00 07/02/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282138
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780140
Principal investigator 1 Boehringer Ingelheim International GmbH $4,500.00 06/23/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780084
Principal investigator 1 Boehringer Ingelheim International GmbH $1,534.00 06/23/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780086
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 06/23/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780088
Principal investigator 1 Genentech, Inc. $8,303.00 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211583951
Principal investigator 1 Genentech, Inc. $9,716.10 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211583955
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,120.00 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281670
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,280.00 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281672
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $574.00 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281674
Principal investigator 1 ABBVIE INC. $7,524.40 06/03/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202488869
Principal investigator 1 ABBVIE INC. $8,895.90 05/14/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202484861
Principal investigator 1 ABBVIE INC. $8,700.90 04/23/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202478606
Principal investigator 1 ABBVIE INC. $11,037.00 04/03/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202471464
Principal investigator 1 ABBVIE INC. $3,374.80 04/03/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202471467
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.83 03/10/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
Proof of Clinical Principal in Crohn's Disease No dispute reported 06/30/2026 1220998971
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 03/06/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780124
Principal investigator 1 Boehringer Ingelheim International GmbH $1,534.00 03/06/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780126
Principal investigator 1 Boehringer Ingelheim International GmbH $4,500.00 03/06/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780128
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780074
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780076
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780078
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780080
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780082
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780130
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780132
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780134
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780136
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780138
Principal investigator 1 Eli Lilly and Company $92.75 02/25/2025 Non-covered Recipient Entity
RESEARCH ALLIANCE INC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187890616
Principal investigator 1 Eli Lilly and Company $15,170.00 02/11/2025 Non-covered Recipient Entity
RESEARCH ALLIANCE INC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187889574
Principal investigator 1 ABBVIE INC. $1,589.90 02/06/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202446975
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780108
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780110
Principal investigator 1 Boehringer Ingelheim International GmbH $3.37 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780112
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780114
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780116
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780118
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780120
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780122